Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

FDA Focusing Enforcement Efforts on GMP Compliance As Off-Label Prosecutions Wane

This article was originally published in The Gold Sheet

Executive Summary

With recent court decisions largely stripping FDA of its powers to take pharmaceutical manufacturers to court for promoting off-label uses, the agency is shifting its enforcement focus to GMP violations, says attorney.


Related Content

Vascular Solutions Not-Guilty Verdict Another Challenge To FDA Off-Label Oversight
FDA Seeks To Resolve First Amendment Suit By Pacira





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst